Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Update

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 108,196 shares, a drop of 22.3% from the December 15th total of 139,273 shares. Based on an average daily volume of 70,912 shares, the days-to-cover ratio is currently 1.5 days. Approximately 2.9% of the shares of the stock are sold short. Approximately 2.9% of the shares of the stock are sold short. Based on an average daily volume of 70,912 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Trading of Oragenics

Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the last quarter. Sabby Management LLC purchased a new stake in shares of Oragenics in the third quarter worth about $77,000. Finally, Clear Street LLC bought a new position in Oragenics during the second quarter valued at approximately $270,000. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Stock Up 1.4%

NYSEAMERICAN OGEN traded up $0.01 during trading hours on Monday, reaching $0.95. The company’s stock had a trading volume of 30,191 shares, compared to its average volume of 50,174. Oragenics has a 1 year low of $0.74 and a 1 year high of $18.90. The company has a market capitalization of $3.96 million, a price-to-earnings ratio of -0.08 and a beta of 0.90. The firm’s 50-day moving average price is $0.91 and its 200-day moving average price is $1.14.

Oragenics (NYSEAMERICAN:OGEN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($1.96) earnings per share (EPS) for the quarter.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.